Citius Pharmaceuticals (CTXR) Retained Earnings (2011 - 2026)

Citius Pharmaceuticals (CTXR) has reported Retained Earnings for 16 consecutive years, with $343.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings rose 16.16% year-over-year to $343.7 million; the trailing twelve-month figure through Jun 2026 stood at $343.7 million (up 16.16% YoY), and the FY2025 full-year result was $306.3 million, up 12.86% from the prior year.
• Retained Earnings advanced to $343.7 million in Q2 2026 per CTXR's latest filing, from $329.8 million in the prior quarter.
• Across five years, Retained Earnings topped out at $343.7 million in Q2 2026 and bottomed at $230.3 million in Q1 2022.
• Historically, Retained Earnings has averaged $271.7 million across 5 years, with a median of $265.3 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Retained Earnings increased 1.61% in 2022, then advanced 18.23% in 2025.
• Over 5 years, Retained Earnings stood at $233.6 million in 2022, then grew by 9.62% to $256.0 million in 2023, then climbed by 8.01% to $276.5 million in 2024, then increased by 18.23% to $327.0 million in 2025, then rose by 5.12% to $343.7 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered $343.7 million, $329.8 million, and $327.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.